Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
Patients with type 2 diabetes who used a smartphone app for cognitive behavioral therapy showed a significant decrease in A1c levels.
Read Full NewsMerck's MK-2214 shows promise in early Alzheimer’s trials, earning FDA fast-track status for its safety and potential efficacy in slowing disease progression.
New STIRUS data unveiled at AES 2025 demonstrate meaningful real-world reductions in seizures, status epilepticus, and healthcare needs with stiripentol in Dravet syndrome.
New findings reveal the challenges of treating pediatric epileptic encephalopathy with NBI-827104, highlighting the need for effective therapies.
5 FDA Headlines You Missed in November 2025
1.
Data-driven risk stratification guides childhood brain tumor treatment, reducing side effects
2.
Early cancer detection during pregnancy and the postpartum period may be aided by breast milk examination.
3.
Five new papers highlight cancer inequities, challenges and opportunities in South Asia
4.
Colorectal Cancer Screening Uptake Tripled in 45-49 Age Group
5.
Report suggests a big improvement in lung cancer survival
1.
Getting to Know RDW and SD: How They Relate to Anemia, Inflammation, and More
2.
Don't Ignore Your Vision Loss: What You Need to Know About Amaurosis Fugax
3.
Understanding Fibrosarcoma: What You Need to Know
4.
Unlocking the Mystery of Leukemia: Exploring New Treatments and Hope for Patients
5.
Gene Signatures and Their Implications in Oncology: Decoding the Blueprint for Personalized Cancer Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part II
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
3.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
4.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
5.
Summary of The Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge